News

Model N Management to Participate in Upcoming Investor Conferences

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced that Model N…

1 year ago

PatientPay Announces Integration with PointClickCare, Enabling Faster and More Seamless Collection of Patient Payments

DURHAM, N.C.--(BUSINESS WIRE)--PatientPay, the leading patient payments partner for acute, ambulatory, and specialty care, today announced an integration with PointClickCare,…

1 year ago

Masimo Announces Full Market Release of Stork™ Smart Home Baby Monitor

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies, today announced the full U.S. market release of…

1 year ago

Unify Medical Announces CRADA Agreement With U.S. Special Operations Command

SCOTTSDALE, AZ / ACCESSWIRE / August 23, 2023 / Unify Medical, Inc., a privately-held, smart surgical visualization technology company, announced…

1 year ago

SmartLabs Sets Roadmap for the Future of Science with New, End-to-End R&D Support

New South San Francisco Location Offers CleanSuites, Broadening Scope of Lab Capabilities to Span Early-Stage R&D through Product CommercializationBOSTON, MA…

1 year ago

CordovaCann (CSE: CDVA / OTCQB: LVRLF) Provides Update on Star Buds Cannabis Co. Retail Operations

Star Buds Cannabis Co. Stores Continue to Show Impressive GrowthTORONTO, ON / ACCESSWIRE / August 23, 2023 / CordovaCann Corp.…

1 year ago

GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR

Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights…

1 year ago

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated…

1 year ago

U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified…

1 year ago

Smart for Life Announces Q2 2023 Financial Results and Provides Business Update

Balance Sheet Transformation Includes Conversion of Over $5.8 Million Debt to Equity Stockholders’ Equity Improves from Deficit of $2.4 Million to…

1 year ago